DailyIQ
Last updatedUpdating…

COR·Cencora, Inc.

$330.11
+5.05 (+1.55%)
Pre-Market
High
$330.29
Open
$330.29
Market Cap
62.19B
52W High
$377.54
Low
$330.29
P. Close
$330.11
P/E
23.69
52W Low
$244.82
Fwd P/E
16.68
DailyIQ Est.
$378.30
Inst. Ownership
47.8%
Short Interest
2.08%
Days to Cover
2.9
Div. Yield
0.73%
Next Ex-Div
~Nov 13
Technical Score (1D)
45
NEUTRAL
News Sentiment
57
BULLISH
COR scores 45 on the 1D technical view with a NEUTRAL signal and mixed momentum. Price action is in a neutral range - the market is coiling, and neither side has been willing to push to a definitive break. Sentiment at 57 is diverging from the flat technical backdrop, removing sentiment as a directional catalyst for now. Consolidations like this are often a sign that the market is waiting for new information before committing capital in either direction. The range between $317.08 and $343.50 is well-defined. When this kind of compression resolves - particularly if it resolves with a gap or range-expansion bar - the follow-through tends to be more sustained than a typical breakout because of the energy that builds during the quiet phase. Coiled setups like this are as much about time as they are about price - the longer COR compresses between $317.08 and $343.50 without a catalyst, the more the eventual move tends to compensate. Watching for a volume spike on the actual break, rather than trying to anticipate direction from the shape of the range, has historically been the more reliable approach.
LOW TARGET
$330 -0.1%
2 analysts
MEAN TARGET
$370 +12.0%
10 analysts
HIGH TARGET
$430 +30.2%
11 analysts
PRICE RANGE
$330.00 - $430.00
SB / B / H / S / SS
5/10/6/1/1
DAILYIQ EST.
$378.30 (+14.5%)
Sector
Healthcare
Industry
Medical Distribution
Exchange
NYQ
Country
United States
Symbol
COR
Description
Cencora, Inc. is a global pharmaceutical distribution and services company, operating through two primary segments: U.S. and International Healthcare Solutions. The company's core business involves the sourcing and distribution of a wide array of pharmaceutical products, including generics, injectables, over-the-counter medications, and specialty pharmaceuticals, serving a diverse customer base encompassing hospitals, pharmacies, and clinics. Cencora also provides value-added services such as pharmacy management, consulting, and data analytics, supporting both healthcare providers and pharmaceutical manufacturers. With a history dating back to 1871, the company, formerly known as AmerisourceBergen Corporation, has established itself as a key player in the healthcare supply chain, offering comprehensive solutions across various healthcare sectors.
Bought (1Y)
8,550 shares
$2.3M
Sold (1Y)
14,551.471 shares
$4.7M
SANCHEZ ROBERT E-
Award/Grant275 shares2026-10-01
Krikorian LazarusSVP & Chief Accounting Officer
Sell986 shares2026-10-01
GREENBERG LON R-
Sell1,280 shares2026-09-16
Krikorian LazarusSVP & Chief Accounting Officer
Sell985 shares2026-09-01
Campbell Elizabeth SExecutive Vice President
Sell11,300.471 shares2026-08-24
59/ 100
Neutral / mixed
Overall: Neutral
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
3.6%
Net Margin
0.5%
Revenue CAGR
9.2%
Current Ratio
0.90x
Debt / Equity
5.08x
Return on Equity
103.1%
Earnings Summary
Cencora, Inc. is a global pharmaceutical distribution and services company operating through U.S. and International Healthcare Solutions segments, providing sourcing, distribution, and value‑added services to hospitals, pharmacies, and clinics. In the latest earnings, Q1 2025 revenue fell to $75.45 billion from $81.49 billion in Q4 2024, while EPS rose from $3.73 to $4.42, both surpassing estimates of $3.52 and $4.10 respectively. Q2 2025 revenue increased to $80.66 billion from $75.45 billion, and EPS climbed to $4.00 from $4.42, still above the $3.84 estimate. Q3 2025 revenue reached $83.73 billion, up from $80.66 billion, with EPS of $3.84 versus the $3.79 estimate, maintaining a consistent EPS beat pattern. In Q2 2026, revenue dipped to $78.36 billion from $83.73 billion, and EPS rose to $4.75 from $4.48, beating the $4.34 estimate. Historically, Cencora has shown a modest YoY revenue decline in recent quarters but has consistently outperformed EPS estimates, indicating efficient cost management. Recent insider sales by a senior executive and the announcement of the upcoming Q4 2026 earnings release suggest heightened investor scrutiny but no operational changes.

EPS

EstBeatMiss
$3.64$3.95$4.27$4.58$4.89Q1'25Q2'25Q3'25Q2'26Q3'26Q4'26
QtrEstActual+/−
Q4'26$4.57 - -
Q3'26$4.39$4.48+2.0%
Q2'26$4.33$4.75+9.6%
Q3'25$3.79$3.84+1.4%
Q2'25$3.84$4.00+4.2%
Q1'25$4.10$4.42+7.9%

Revenue

EstBeatMiss
$73.4B$77.8B$82.2B$86.5B$90.9BQ1'25Q2'25Q3'25Q2'26Q3'26Q4'26
QtrEstActual+/−
Q4'26$88.9B - -
Q3'26$85.2B$84.8B-0.5%
Q2'26$87.2B$78.4B-10.2%
Q3'25 - $83.7B -
Q2'25 - $80.7B -
Q1'25 - $75.5B -

Market Data

COR Stock Snapshot

NEUTRAL45/100
$330.29+$0.51 (0.2%)
Market cap
62.19B
P/E ratio
23.7
Day range
$330.29 – $330.29
News sentiment
57/100 · Neutral
Analyst target
$369.92 (+12.0%)
Consensus
Buy · 23 analysts
52-week range+34.9% off low · -12.5% from high
$244.82$377.54
Price $330.29 DailyIQ Est. $378.30

COR sits in the middle of its 52-week range with the technical picture unresolved. Sector peers are worth watching - large caps in Healthcare tend to move together on rotation.

Reverse DCF

What growth is priced into COR?

CHEAP

At today's price, Cencora, Inc. needs to grow free cash flow about -1.7% a year for the next 10 years to justify its valuation at a 6.55% cost of capital. Over its actual history it has compounded free cash flow at 8.7% a year, so the market is asking for 10.4 percentage points below its own delivered rate. On that basis COR looks priced below what its own growth record supports.

Implied FCF growth
-1.7%
Historical FCF CAGR
8.7%
Growth gap
-10.4 pts
Verdict
CHEAP
Discount rate (WACC)
6.55%
Beta
0.31

Behaviour On Record

What COR's own history says about today's numbers

Realized volatility (21d)
24.1% 65th pct
Below its peak
-13.6%
vs 200-day average
+2.0%
Up days (1y)
53%

Cencora, Inc. is currently running 24.1% annualised volatility over the last 21 sessions. Measured against COR's own 13 years of daily returns rather than a market-wide average, that is the 65th percentile — a little above its own norm, against a typical reading of 21.2%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

COR is trading -13.6% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -18.3%, and the deepest was -33.0% in 2016. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits +2.0% from its 200-day moving average. Against every other day in its history, that gap ranks at the 35th percentile — close to the gap it normally carries. Over the past year COR closed higher on 53% of sessions, and it is currently 2 sessions into a rising streak.

On October specifically: over 13 years of records, COR finished the month higher 9 of 13 times, with a median return of +2.1% and an average of +1.8%. Its strongest month historically has been November at +4.8% on average, its weakest August at -1.9%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: COR has opened more than 2% away from the prior close in 91 of 3,266 sessions (2.8% of the time), with the largest gaps running +6.6% and -11.1%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

All figures computed from 3,267 daily closes between 2013-10-14 and 2026-10-09, split-adjusted, recomputed daily. Percentiles are against COR's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of COR's sector?

Cencora, Inc. sits in the Health Care sector, currently ranked 5th of 12 GICS sectors by relative-strength rotation score (improving).

Sector rank
#5 of 12
Sector state
Improving
Sector rotation score
64

Options Market

What is the options market pricing for COR?

CallsPuts

For Cencora, Inc.'s nearest expiry (2026-11-20, 37 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.00), with at-the-money implied volatility around 3.1%. The options market is pricing roughly a ±1.0% move by that expiry — a range of about $314.30–$320.62.

Put/call ratio (2026-11-20)
0.00
ATM implied volatility
3.1%
Total open interest
13
Expected move by 2026-11-20
±1.0% ($314.30–$320.62)

Analyst Rating Changes

Are analysts turning bullish or bearish on COR?

Leerink Partners most recently reiterated its rating on Cencora, Inc. to Outperform on Oct 7, 2026 with a price target of $388 (from $380). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
Leerink Partners — Outperform
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Oct 7, 2026Leerink PartnersMaintainedOutperform$380 → $388
Sep 8, 2026RBC CapitalReiteratedSector Perform$330
Aug 19, 2026RBC CapitalInitiatedSector Perform$330
Aug 11, 2026Wells FargoMaintainedOverweight$331 → $395
Aug 7, 2026Morgan StanleyMaintainedOverweight$342 → $346
Aug 7, 2026JP MorganMaintainedOverweight$382 → $390
Aug 6, 2026UBSMaintainedBuy$412 → $430
Aug 6, 2026Evercore ISI GroupMaintainedOutperform$330 → $350
Jun 24, 2026B of A SecuritiesMaintainedNeutral$280 → $285
Jun 10, 2026BarclaysMaintainedOverweight$425 → $350
May 11, 2026Wells FargoMaintainedOverweight$429 → $331
May 7, 2026UBSMaintainedBuy$410 → $412

Peers & ETF holders

COR peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

57/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Cencora (NYSE:COR) posted an annualized return of 20.2% over the past decade, outpacing the broader market by 6.46%. The company’s performance propels its market capitalization to $60.54 billion. The data highlights long‑term value creation but does not indicate any new catalysts or changes in guidance.
What did this article say?
Cencora (NYSE:COR) conducted its third‑quarter earnings conference call on October 8, 2026. The call provided a detailed discussion of the company’s financial performance, operational highlights, and strategic outlook. Executives addressed revenue growth, cost management, and future guidance, offering insights into the company’s trajectory. The transcript was made publicly available through Benzinga’s API service.
What did this article say?
Leerink Partners analyst Michael Cherny upgraded Cencora (NYSE:COR) to an Outperform rating on October 7. The firm increased its price target from $380 to $388, reflecting confidence in the company’s growth prospects. The upgrade signals a positive outlook for COR’s earnings trajectory and market position. The rating change is expected to influence investor sentiment and potentially lift the stock price. The adjustment underscores Leerink’s belief in Cencora’s strategic initiatives and financial performance.
What did this article say?
Leerink Partners raised its price target for Cencora (COR) to $388 from $380, reflecting a more optimistic view of the company’s prospects. The brokerage cited improved earnings guidance and a stronger competitive position in the pharmaceutical sector as key drivers. The upgrade aligns with an overweight rating and a mean target of $369.50 among analysts. This move signals confidence in COR’s ability to generate higher returns and may influence investor sentiment.
What did this article say?
On October 1, 2026, Lazarus Krikorian, Cencora’s Senior Vice President and Chief Accounting Officer, sold 986 shares of the company for $298,935, as disclosed in a Form 4 filing. The transaction reduced his holdings to 15,183 shares, leaving him with a total of 15,183 common shares. The sale was reported in a standard SEC filing and does not indicate any immediate operational or financial change for Cencora. However, the insider sale may be viewed by investors as a potential negative signal regarding the company’s outlook.
What did this article say?
Cencora, Inc. announced that it would release its Fourth Quarter Fiscal 2026 earnings on Wednesday, November 4, 2026, ahead of the New York Stock Exchange opening. The company scheduled a conference call at 8:30 a.m. ET to discuss the results. The announcement provides the market with the exact date and time for the upcoming earnings report.
What did this article say?
Cencora (NYSE:COR) delivered an average annual return of 20.45% over the past five years, outperforming the broader market by 8.44% on an annualized basis. The company’s market capitalization reached $57.98 billion as of the report. The sustained performance reflects strong revenue growth and operational efficiency. Investors who purchased shares five years ago would see significant capital appreciation. The data underscores COR’s robust competitive position in the industrial sector.
What did this article say?
Cencora (COR) announced the election of Robert Sanchez, former chairman and CEO of Ryder Systems, to its board of directors effective October 1. Sanchez will serve as an independent director, bringing experience from the logistics and transportation industry. The appointment follows his retirement from Ryder Systems in March and is part of Cencora’s ongoing efforts to strengthen its governance structure. No immediate operational or financial implications were disclosed, and the move is viewed as a routine corporate governance update.
What did this article say?
Cencora, Inc. announced on September 25, 2026 that it had elected Robert E. Sanchez, former CEO of Ryder System, as a new independent director effective October 1, 2026. Sanchez’s experience in logistics, supply chain management, and corporate governance was highlighted as complementary to Cencora’s pharmaceutical‑centric strategy. The appointment signals the board’s intent to leverage his operational and financial expertise to support the company’s growth ambitions.

Technical Analysis

Real-time indicators across multiple timeframes

45
NEUTRAL
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $26.53B combined position · 13 adding, 12 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▲ Buy23,617,11712.54%$7.98B2026-01-29
BlackRock, Inc.▼ Sell18,213,7839.67%$5.15B2026-08-07
JPMorgan Chase & Co▲ Buy5,943,6573.16%$1.67B2026-08-12
Geode Capital Management, LLC▼ Sell5,454,8882.90%$1.54B2026-08-12
Wellington Management Group LLP▲ Buy4,559,7612.42%$1.29B2026-08-14
FMR LLC (Fidelity)▼ Sell4,122,3712.19%$1.17B2026-08-13
Morgan Stanley▼ Sell4,086,2712.17%$1.16B2026-08-13
Bank of America Corp▼ Sell3,733,9211.98%$1.06B2026-08-14
Norges Bank▲ Buy2,473,8251.31%$700.04M2026-08-12
Goldman Sachs Group Inc▲ Buy2,274,1481.21%$643.54M2026-08-14
Northern Trust Corp▼ Sell2,158,9391.15%$610.94M2026-08-13
Invesco Ltd.▼ Sell2,021,2341.07%$571.97M2026-08-14
Capital Research Global Investors▲ Buy1,979,9421.05%$560.28M2026-08-12
Citadel Advisors LLC▲ Buy1,366,6470.73%$386.73M2026-09-02
Wells Fargo & Company▼ Sell1,285,4210.68%$363.75M2026-08-14
Neuberger Berman Group LLC▲ Buy1,174,2690.62%$332.18M2026-08-13
Millennium Management LLC▲ Buy950,4790.50%$268.97M2026-08-14
AllianceBernstein L.P.▼ Sell653,4720.35%$205.28M2026-08-14
Balyasny Asset Management L.P.▲ Buy608,6120.32%$172.23M2026-08-14
Point72 Asset Management, L.P.▲ Buy604,7460.32%$171.13M2026-08-14
Squarepoint Ops LLC▲ Buy544,2950.29%$154.02M2026-08-14
Janus Henderson Group plc▼ Sell389,5420.21%$122.37M2026-05-18
Marshall Wace, LLP▲ Buy342,1760.18%$96.83M2026-08-13
Citigroup Inc▼ Sell279,9040.15%$79.21M2026-08-03
AQR Capital Management LLC▼ Sell272,7280.14%$76.38M2026-08-14
Q2 2026 flow:4.27M sh bought ($1.21B)7.65M sh sold ($2.17B)net -3.37M sh (−$960.45M)
Congressional Trading Activity
6 disclosed trades · ~$139.5K est. traded value · 3 buys, 3 sells
MemberChamberStateTypeAmountTradedFiled
Jared MoskowitzHouseFL23▼ Sell$1K - $15K2026-05-062026-06-19
Jared MoskowitzHouseFL23▲ Buy$1K - $15K2026-03-312026-04-30
Alan ArmstrongSenateOK▲ Buy$1K - $15K2026-03-272026-07-21
Jared MoskowitzHouseFL23▲ Buy$1K - $15K2026-03-232026-04-30
Jefferson ShreveHouseIN06▼ Sell$50K - $100K2025-05-122025-06-22
Greg LandsmanHouseOH01▼ Sell$15K - $50K2025-03-272025-04-08